Posted by Michael Wonder on 15 Nov 2023
Lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with metastatic PSMA positive hormone-relapsed prostate cancer after two or more treatments
15 November 2023 - NICE has published final evidence-based recommendations on the use of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for the treatment of adults with metastatic prostate-specific membrane antigen-positive hormone-relapsed prostate cancer after two or more treatments.
Lutetium Lu 177 vipivotide tetraxetan is not recommended for the treatment of adults with metastatic PSMA positive hormone-relapsed prostate cancer after taxane-based chemotherapy and an anti-androgen or when the use of a taxane is 'medically unsuitable'.
